Related Experiment Video
Updated: Aug 17, 2026
06:48
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study
Jacek A Kopec1, Vivek Goel, Peter S Bunting
1Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada. jkopec@arthritisresearch.ca
The Journal of Urology
|July 12, 2005
Summary
Prostate specific antigen (PSA) screening in asymptomatic men was associated with a reduced risk of metastatic prostate cancer. Further research is needed to confirm these findings in randomized controlled trials.
Area of Science:
- Urology
- Oncology
- Public Health
Background:
- Prostate specific antigen (PSA) screening for prostate cancer in asymptomatic men is controversial.
- Evidence for PSA screening's effectiveness in reducing prostate cancer mortality is limited.
Purpose of the Study:
- To determine if PSA screening reduces the risk of developing metastatic prostate cancer.
Main Methods:
- Population-based case-control study in Metropolitan Toronto and surrounding counties.
- 236 metastatic prostate cancer cases and 462 controls were analyzed.
- Data collected via medical records and self-administered questionnaires.
Main Results:
- Asymptomatic men who were screened with PSA had a lower frequency of metastatic prostate cancer (OR 0.65).
- Reduced risk observed in younger men (45-59 years, OR 0.52) and older men (60-84 years, OR 0.67).
Conclusions:
- PSA screening in asymptomatic men showed an association with a reduced risk of metastatic prostate cancer.
- Results require confirmation through randomized controlled trials.